Sheikh Mohammed funds Katia's AED 8.8m SMA treatment at Al Jalila

Sheikh Mohammed bin Rashid Al Maktoum will sponsor AED 8.8 million treatment at Al Jalila Children's Hospital in Dubai for Katia Abu Al-Seoud, a one-year-old Jordanian child with spinal muscular atrophy, according to Emirates 24|7.

The highest-stakes readers are CFOs, COOs and medical directors. For CFOs, the case puts a single paediatric medicine in the same cost band as a small clinic acquisition. For COOs and medical directors, it shows how fast diagnosis, genetic testing, payer clearance and referral pathways must work when an infant may be eligible for one-time gene therapy before age two.

What happened in Dubai

Emirates 24|7 reported on 20 August 2026 that Katia's parents reacted after learning that Sheikh Mohammed, Vice President and Prime Minister of the UAE and Ruler of Dubai, would sponsor her treatment for spinal muscular atrophy. The earlier Emirates 24|7 report said her mother had posted a video appeal seeking help for treatment that the family could not afford.

The case is centred on Dubai because the treatment is reported to be at Al Jalila Children's Hospital. Dubai facilities are regulated by the Dubai Health Authority (DHA), while Al Jalila is part of Dubai Health. Abu Dhabi and Al Ain operators should benchmark against the Department of Health Abu Dhabi (DOH) pathway. Clinics in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain should route licensing and facility questions through the Ministry of Health and Prevention (MOHAP).

Dubai has prior infrastructure for this disease. The Government of Dubai Media Office said on 11 November 2020 that Al Jalila would introduce Zolgensma, also known as AVXS-101, for the first time in the UAE. The same announcement said the hospital could manage clinical identification, genetic diagnosis, infusion and follow-up under one roof.

The cost problem for payers

The AED 8.8 million figure is the actionable number for finance teams. It is close to the global price band for onasemnogene abeparvovec, the gene therapy sold as Zolgensma. The US list price at launch was reported at $2.125 million, equal to about AED 7.8 million at the UAE dollar peg, before hospital, testing, monitoring and logistics costs.

Insurers should treat SMA as a case-management issue rather than a routine pre-authorisation file. Daman and Thiqa in Abu Dhabi, and private insurers such as Sukoon in Dubai and the northern emirates, should verify policy wording for rare diseases, gene therapy, named-patient access, exclusions, government programmes and charity co-funding. The practical question is who signs off when a clinician says treatment timing affects eligibility.

• Age: Zolgensma is generally used for children under two, subject to the treating specialist's assessment and applicable label or local approval.
• Diagnosis: providers need confirmed SMN1 genetic testing and usually SMN2 copy-number information.
• Pre-infusion checks: teams typically assess liver function, cardiac markers, weight and anti-AAV9 antibody status.
• Follow-up: post-infusion monitoring can include corticosteroids, liver tests, platelet checks and motor assessments.

Those items should be priced before a public appeal is needed. For a maternity hospital, the operational test is whether a hypotonia case can reach paediatric neurology and genetics within days. For an insurer, the test is whether a rare-disease file has an escalation route measured in hours, not weeks.

Why clinics should pay attention

The UAE has local data. A 2024 Communications Medicine study led by UAE-based researchers screened 1,502 healthy Emirati newborns and estimated an SMA carrier frequency of 1.3%, or 1 in 79. The same paper estimated UAE incidence at 1 in 7,122 live births and said Al Jalila's Genomics Centre received suspected paediatric SMA referrals between June 2019 and August 2023.

Al Jalila has also moved beyond first-case status. Dubai Health said on 5 June 2026 that Al Jalila had completed more than 100 SMA treatments since the first patient in 2020. That gives Dubai a regional reference point for tertiary paediatric neurology, genetics, rehabilitation and payer coordination.

For patients, the lesson is direct. Families should ask a licensed paediatrician or paediatric neurologist for written referral criteria, genetic testing requirements, expected turnaround time, and whether the case should go to a tertiary paediatric centre in Dubai or Abu Dhabi. For clinics, the compliance step is to keep referral records, consent forms and insurer decisions complete enough for DHA, DOH or MOHAP review if the case later escalates.

The next question is whether high-cost rare-disease pathways become predictable before another family turns to social media. UAE operators can start with their licensed referral network, payer escalation process and paediatric genetics access. For licensed clinics and providers by emirate, readers can search the UAE Open Healthcare Directory.